people with HS compared with controls when adjusting for age and sex in univariate analysis, but not by multivariate analysis. However, in analyses stratified by severity (using the modified Hurley score) resting mean heart rate was significantly higher in people with severe HS. The authors observed that patients with mild HS have a shorter QRS duration and that HS is not associated with changes in the PR interval, JTcF interval or QTcF interval.Patients with HS tend to have a higher body mass index (BMI) compared with controls, and BMI is correlated with HS severity. Obesity is linked with increased heart rate and increased sympathetic activity. 5 The sympathetic predominance and augmented inflammation in HS may be the possible link between severe HS and increased heart rate. As increased resting heart rate is associated with increased risk of cardiovascular mortality, Juhl et al. concluded that increased heart rate is a potentially important and easily testable marker associated with increased risk of cardiovascular mortality and sudden death. The studies about the association between HS and metabolic syndrome follow the studies about the association between psoriasis and metabolic syndrome. In 2006, the first study described the association between psoriasis and metabolic syndrome.7 Two years later, in 2008, the American Journal of Cardiology Editor's Consensus on Psoriasis and Coronary Artery Disease recommended that patients with moderate to severe psoriasis should be evaluated for personal and family history of coronary artery disease and recommended annual assessment of blood pressure, screening of lipid profiles and fasting blood glucose. They also recommended treatment of risk factors for coronary artery disease in patients with moderate to severe psoriasis. 8 As the association between HS and metabolic syndrome has already been established, the observations published by Juhl et al. in this issue of the BJD further support these observations and may have substantial clinical relevance.As it is recommended to identify and reduce cardiovascular risk in patients with moderate to severe psoriasis, it is not unreasonable to extrapolate this recommendation from psoriasis to severe HS. As this risk is further verified, it may, in time, lead to the development of consensus guidelines for the identification and treatment of coronary artery disease risk factors in patients with severe HS.
Conflicts of interest